Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for bluebird bio, Inc. (BLUE)

« Back to company index

BLUE Chatter Timeline

Stock Ticker for BLUE

Most Active Tweeters for BLUE

UserTweets
@portefeuillefun 6
@AmericanBanking 6
@TheBiotechBeat 4
@_B_I_O_T_E_C_H_ 4
@Feldt18611025 3

Recent Tweets for BLUE

LeanneSpurs @LeanneSpurs
@JuliaHB1 What colour was the dress that featured in Bill Clinton's scandal & impeachment in 1998? $Blue
June 17th 2019, 10:06pm
42Stocks @42Stocks
bluebird bio up 4.3% = $278.9 million gain. $BLUE has made notable gains in 15 of the last 33 trading sessions, 4 d… https://t.co/j75WcJfY2m
June 17th 2019, 5:06pm
AmericanBanking @AmericanBanking
bluebird bio $BLUE PT Set at $120.00 by Piper Jaffray Companies https://t.co/EgxkxLXkCQ #stocks
June 17th 2019, 4:06pm
semodough @semodough
$BLUE Phase I/II trial (NCT02151526) evaluating the efficacy and safety of LentiGlobin BB305 Drug Product in Beta-T… https://t.co/dqPHglcbcl
June 17th 2019, 12:06pm
AmericanBanking @AmericanBanking
bluebird bio’s $BLUE Outperform Rating Reiterated at BMO Capital Markets https://t.co/NJNq5Qhofb #stocks
June 17th 2019, 11:06am
portefeuillefun @portefeuillefun
Sold 50 $BLUE at $122.23, now 300 #vssporte shares.
June 17th 2019, 10:06am
eatyourselfcool @eatyourselfcool
RT @BehaviorFin: $GBT how do you read the results ? #sicklecell $BLUE
June 17th 2019, 5:06am
sesiegler @sesiegler
Will $BLUE see Glybera’s pricing as a warning sign? Probably not. Some executives just don’t get it, and it appear… https://t.co/Zm3ecyaXQn
June 16th 2019, 5:06pm
HottestStockNow @HottestStockNow
$BLUE Reveals new findings from ongoing early-stage study evaluating LentiGlobin for sickle cell disease https://t.co/X8iYFEnL4X
June 16th 2019, 3:06pm
PredatorDiaries @PredatorDiaries
RT @adamfeuerstein: Update: Per $BLUE spox — apheresis procedure, associated drugs & autologous stem cell transplant procedure (preconditio…
June 16th 2019, 5:06am
BioinformaticsB @BioinformaticsB
RT @BioinformaticsB: $BLUE gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate httpswww.statnews.com201906…
June 15th 2019, 11:06pm
ebcapital @ebcapital
Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous? @themotleyfool #stocks $BLUE #biotech #genetics… https://t.co/gR9Yf50e5s
June 15th 2019, 6:06pm
Gambiste1 @Gambiste1
RT @buysidebio: Thx Adam. It also appears that the ultimate commercial success of $BLUE will rely on $MGTA given the 3hr potential mobiliza…
June 15th 2019, 10:06am
buysidebio @buysidebio
Thx Adam. It also appears that the ultimate commercial success of $BLUE will rely on $MGTA given the 3hr potential… https://t.co/3bGoqsuigV
June 15th 2019, 10:06am
ideapharma @ideapharma
@JorgeCondeBio It’s unclear what $NVS or $BLUE are optimising for: - leadership in the space (learning by doing) -… https://t.co/3Srnb0NmnQ
June 15th 2019, 9:06am
ZolmaxNews @ZolmaxNews
bluebird bio Inc $BLUE Insider Sells $175,616.00 in Stock https://t.co/ptf6GSuK2P
June 15th 2019, 9:06am
SickEconomics @SickEconomics
$BLUE is charging $1.8M for it's pioneering gene therepy in Europe. But it will accept installment payments, and if… https://t.co/v8AkHQ3ZJA
June 15th 2019, 7:06am
BioStocks @BioStocks
$BLUE sets $1.8M price tag for blood-disease gene therapy Zynteglo https://t.co/sZMzxcT0Ln #biotech
June 15th 2019, 7:06am
stocknewstimes @stocknewstimes
JPMorgan Chase & Co. Reiterates Buy Rating for bluebird bio $BLUE https://t.co/PCbbQt4a25
June 15th 2019, 3:06am
SleekMoneycom @SleekMoneycom
JPMorgan Chase & Co. Reiterates Buy Rating for bluebird bio $BLUE https://t.co/3H2ERMfOM2 #investing
June 15th 2019, 3:06am
Gambiste1 @Gambiste1
RT @Stock_Truth: $BLUE Wow, despite approval their launch delayed due to manufacturing changes requested by EMA. $SRPT not having to be th…
June 15th 2019, 2:06am
BursatilBiotech @BursatilBiotech
@ByJonGardner , $BLUE used the same slides as in #JPM19 https://t.co/Pb5gFI5GO3
June 15th 2019, 12:06am
BursatilBiotech @BursatilBiotech
Does anyone remember about $BLUE's presentation back at #JPM19 on pricing & pmt model? If not, here it is. https://t.co/vfe3AyIL2n
June 15th 2019, 12:06am
Stock_Truth @Stock_Truth
$BLUE Wow, despite approval their launch delayed due to manufacturing changes requested by EMA. $SRPT not having t… https://t.co/OH1p4waIyd
June 14th 2019, 10:06pm
GuruHavenHQ @GuruHavenHQ
RT @KobesyTrades: CEO of $BLUE on @CNBC trying to explain a $1.8mm drug ... just wild. Well, looks like his stock is going to get bearish e…
June 14th 2019, 8:06pm
Emerald_CG @Emerald_CG
RT @DZalkowitz: $BLUE journalists are doing such a terrible job of headlines with regards to the pricing here - it's over the course of 5 Y…
June 14th 2019, 8:06pm
princetongb @princetongb
@ByJonGardner Here comes the $BLUE deflation...
June 14th 2019, 8:06pm
EMcCallister01 @EMcCallister01
RT @jeff_cranmer: $BLUE is set to be 1st to test an outcomes-based pricing model for a #GeneTherapy where the vast majority of the price is…
June 14th 2019, 7:06pm
jeff_cranmer @jeff_cranmer
$BLUE is set to be 1st to test an outcomes-based pricing model for a #GeneTherapy where the vast majority of the pr… https://t.co/CgaYNxJOVZ
June 14th 2019, 7:06pm
MathaCMU @MathaCMU
RT @adamfeuerstein: $BLUE gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate https://t.co/lbSO50euM2
June 14th 2019, 7:06pm
Rondo49 @Rondo49
RT @MaxSpeculation: $BLUE https://t.co/j0eelnJF4D
June 14th 2019, 7:06pm
PeterRSerafini @PeterRSerafini
RT @JohnCendpts: $BLUE did a particularly poor job in setting up the pricing discussion today for the world's second priciest therapy. The…
June 14th 2019, 7:06pm
MaxSpeculation @MaxSpeculation
$BLUE https://t.co/j0eelnJF4D
June 14th 2019, 7:06pm
syinvesting @syinvesting
BMO comments on $BLUE Zynteglo launch delay to 2020: - Company needs to improve drug product specifications & manu… https://t.co/gnbkg4qT3n
June 14th 2019, 5:06pm
jeromeverony @jeromeverony
RT @ByJonGardner: Piper Jaffray on $BLUE. https://t.co/xp3qyAYXhk
June 14th 2019, 5:06pm
endpts @endpts
RT @JohnCendpts: Top 3 today -- #1 UPDATED: Bluebird shares sink as analysts puzzle out $1.8M sticker shock and an unexpected delay $BLUE…
June 14th 2019, 5:06pm
TheBiotechBeat @TheBiotechBeat
RT @ByJonGardner: $BLUE sickle cell data. https://t.co/QyKvmhYUeM
June 14th 2019, 5:06pm
TheBiotechBeat @TheBiotechBeat
RT @jonathanrockoff: $BLUE prices its Zynteglo gene therapy for beta thalassemia blood disorder at $1.8mn in Europe, which recently approve…
June 14th 2019, 5:06pm
PredatorDiaries @PredatorDiaries
@ByJonGardner That's Piper out of the next $BLUE secondary
June 14th 2019, 5:06pm
TheBiotechBeat @TheBiotechBeat
RT @adamfeuerstein: $BLUE Zynteglo EU launch delayed to end of 2019, per Cowen note. I hadn’t seen/heard this before. See below. https://t.…
June 14th 2019, 5:06pm
TheBiotechBeat @TheBiotechBeat
RT @JohnCendpts: $BLUE from SVB Leerink: More concerning is that BLUE was unable to execute on the manufacturing process development that i…
June 14th 2019, 5:06pm
ByJonGardner @ByJonGardner
Piper Jaffray on $BLUE. https://t.co/xp3qyAYXhk
June 14th 2019, 5:06pm
JonTrading058 @JonTrading058
RT @theflynews: Bluebird Bio launch of Zynteglo delayed in EU, says Cowen $BLUE https://t.co/OAo9nXiii2
June 14th 2019, 4:06pm
MaisaCorp @MaisaCorp
$BLUE set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after win… https://t.co/4L2PfINpmb
June 14th 2019, 4:06pm
portefeuillefun @portefeuillefun
RT @_B_I_O_T_E_C_H_: @JohnCendpts $BLUE Leerink https://t.co/QsOmcpoYB4
June 14th 2019, 4:06pm
portefeuillefun @portefeuillefun
RT @_B_I_O_T_E_C_H_: Raymond James $BLUE "Failure to Launch: Zynteglo Refuses to Leave the Nest Until 2020"
June 14th 2019, 3:06pm
_B_I_O_T_E_C_H_ @_B_I_O_T_E_C_H_
Raymond James $BLUE "Failure to Launch: Zynteglo Refuses to Leave the Nest Until 2020"
June 14th 2019, 3:06pm
dshahh @dshahh
RT @JohnCendpts: Sticker shock: Bluebird bio sets a $1.8M European price on its newly approved gene therapy $BLUE https://t.co/Hf0dBr82IS
June 14th 2019, 3:06pm
_B_I_O_T_E_C_H_ @_B_I_O_T_E_C_H_
@JohnCendpts $BLUE Leerink https://t.co/QsOmcpoYB4
June 14th 2019, 3:06pm
MarketChmln @MarketChmln
$BLUE $BLUE share price decreases -6.0%. See recent news release. https://t.co/rv3uXTbhWT
June 14th 2019, 3:06pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.